NASDAQ:PHAR

Pharming Group Stock Forecast, Price & News

$12.80
-0.46 (-3.47 %)
(As of 04/12/2021 03:50 PM ET)
Add
Compare
Today's Range
$12.80
Now: $12.80▼
$12.96
50-Day Range
$12.44
MA: $13.33▼
$13.82
52-Week Range
$12.24
Now: $12.80▼
$21.99
Volume994 shs
Average Volume8,767 shs
Market Capitalization$816.72 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Pharming Group N.V., a specialty pharmaceutical company, develops and manufactures biopharmaceutical products in the United States, Europe, and internationally. The company's lead product is Ruconest, a recombinant human C1 esterase inhibitor that is used for the treatment of acute hereditary angioedema in Europe, the United States, Israel, and South Korea. It also engages in the development of recombinant human factor VIII (rhFVIII) for the treatment of haemophilia A; and protein replacement treatments for enzyme-deficiency disorders, such as pompe and fabry diseases, as well as products for acute kidney injury. The company has partnerships with China State Institute of Pharmaceutical Industry and the Chengdu Institute of Biological Products for the development of new products; and development collaboration and license agreement with Novartis to develop and commercialize leniolisib (CDZ173), a small molecule phosphoinositide 3-kinase delta inhibitor to treat patients with activated phosphoinositide 3-kinase delta syndrome. Pharming Group N.V. is headquartered in Leiden, the Netherlands.

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Biotechnology
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:PHAR
Previous Symbol
CUSIPN/A
CIKN/A
Webwww.pharming.com
Phone31 71 524 7400
Employees258
Year FoundedN/A

Debt

Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / Cash FlowN/A
Book ValueN/A
Price / BookN/A

Profitability

EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A

Miscellaneous

Outstanding Shares63,806,000
Market Cap$816.72 million
Next Earnings DateN/A
OptionableNot Optionable

Headlines

Pharming Group announces the filing of its 2020 Annual Report on Form 20-F with the U.S. Securities and Exchange Commission
April 7, 2021 |  finance.yahoo.com
Pharming Group (NASDAQ:PHAR) Short Interest Up 228.9% in March
March 28, 2021 |  americanbankingnews.com
Here's what Wall Street expects from Pharming Group NV American Depositary Shares Repr 10's earnings
March 2, 2021 |  markets.businessinsider.com
Pharming Group NV earnings: here's what Wall Street expects
March 2, 2021 |  markets.businessinsider.com
Pharming Group, in collaboration with Invitae Corporation, launches genetic testing program 'navigateAPDS' in US and Canada
March 2, 2021 |  finance.yahoo.com
See More Headlines

MarketRank™

Overall MarketRank™

0.00 out of 5 stars

Medical Sector

2007th out of 2,011 stocks

Biotechnology Industry

140th out of 143 stocks

Analyst Opinion: 0.0Community Rank: 0.0Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -
$12.80
-0.46 (-3.47 %)
(As of 04/12/2021 03:50 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive PHAR News and Ratings via Email

Sign-up to receive the latest news and ratings for PHAR and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Pharming Group (NASDAQ:PHAR) Frequently Asked Questions

What stocks does MarketBeat like better than Pharming Group?

Wall Street analysts have given Pharming Group a "N/A" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Pharming Group wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Pharming Group?

Pharming Group saw a increase in short interest in the month of March. As of March 15th, there was short interest totaling 37,500 shares, an increase of 228.9% from the February 28th total of 11,400 shares. Based on an average trading volume of 30,400 shares, the short-interest ratio is presently 1.2 days.
View Pharming Group's Short Interest.

How were Pharming Group's earnings last quarter?

Pharming Group (NASDAQ:PHAR) released its earnings results on Thursday, March, 4th. The company reported $0.13 earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of $0.01 by $0.12. The firm earned $60.80 million during the quarter, compared to analyst estimates of $61.69 million.
View Pharming Group's earnings history.

Who are Pharming Group's key executives?

Pharming Group's management team includes the following people:
  • Dr. Sijmen de Vries M.B.A., M.D., MBA, Exec. Director & CEO (Age 62)
  • Dr. Bruno M. L Giannetti, Chief Medical Officer (Age 69)
  • Mr. Jeroen Wakkerman, Chief Financial Officer (Age 52)
  • Ms. Mireille Sanders M.Sc., Chief Operations Officer (Age 53)
  • Dr. Pericles Calias, Chief Scientific Officer (Age 53)
  • Susanne Embleton, Investor Relations Mang.
  • Ms. Anne-Marie de Groot M.A., Chief Ethics & Compliance Officer (Age 40)
  • Mr. Paul Th. Jansse, VP & Head of Non-US Commercial Operations (Age 52)
  • Mr. Stephen Toor, Chief Commercial Officer & GM of Americas (Age 50)

Who are some of Pharming Group's key competitors?

Some companies that are related to Pharming Group include Genus (GNS), Abcam (ABC), BTG (BTG), Seer (SEER), MorphoSys (MOR), Nuvation Bio (NUVB), ImmunityBio (IBRX), BioAtla (BCAB), Immunocore (IMCR), Cullinan Oncology (CGEM), Cricut (EWTX), Kinnate Biopharma (KNTE), Silverback Therapeutics (SBTX), Trillium Therapeutics (TRIL) and Nurix Therapeutics (NRIX).
View all of PHAR's competitors.

What is Pharming Group's stock symbol?

Pharming Group trades on the NASDAQ under the ticker symbol "PHAR."

How do I buy shares of Pharming Group?

Shares of PHAR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Pharming Group's stock price today?

One share of PHAR stock can currently be purchased for approximately $12.80.

How much money does Pharming Group make?

Pharming Group has a market capitalization of $816.72 million.

How many employees does Pharming Group have?

Pharming Group employs 258 workers across the globe.

What is Pharming Group's official website?

The official website for Pharming Group is www.pharming.com.

How can I contact Pharming Group?

The company can be reached via phone at 31 71 524 7400.


This page was last updated on 4/12/2021 by MarketBeat.com Staff

As Featured By:

MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.